SCGB2A2

Across TCGA pan-cancer cohorts, SCGB2A2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SCGB2A2 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher SCGB2A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SCGB2A2 expression acts as an unfavorable survival marker.

DLBC, LUAD, and LIHC are the cancer types where SCGB2A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
LUAD	DFS	Median	All	0.098	0.791	<.001	18	view →
LIHC	OS	Median	III,IV	0.270	0.732	.021	6	view →
LUSC	OS	Median	All	0.192	0.724	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SCGB2A2–DLBC (OS)

Open the DLBC breakdown →